FDA spending could be tightened under Republicans
This article was originally published in Scrip
While there's a good chance the FDA could gain some new funding under the 21st Century Cures Initiative, which is being led by members of the House, once Republicans take control of the Senate in January, the agency's spending may come under tighter scrutiny, said Washington lawyer John R Manthei, a partner at Latham & Watkins and global co-chair of the firm's healthcare and life sciences practice.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.